Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

NXE-0048149 is under clinical development by Nxera Pharma and currently in Phase I for Psychosis. According to GlobalData, Phase I drugs for Psychosis have a 59% phase transition success rate (PTSR) ...

Her doctor was on board, so long as Hasan also agreed to start resistance training—something she had only done briefly in the ...

A recent breakthrough in medical research offers exciting possibilities for people dealing with diabetes and obesity. This ...

Here are the top medical news for the dayStudy Shows Non-Opioid Alternatives Outperform Opioids for Post-Dental Surgery Pain A combination of acetaminophen (Tylenol) and ibuprofen (Advil, ...

Health care professionals should explore the use of glucagon-like peptide-1 receptor agonists (GLP1RAs ... STRIDE = A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...